CN1352686A - 细胞因子受体链 - Google Patents

细胞因子受体链 Download PDF

Info

Publication number
CN1352686A
CN1352686A CN99815591A CN99815591A CN1352686A CN 1352686 A CN1352686 A CN 1352686A CN 99815591 A CN99815591 A CN 99815591A CN 99815591 A CN99815591 A CN 99815591A CN 1352686 A CN1352686 A CN 1352686A
Authority
CN
China
Prior art keywords
amino acid
protein
seq
binding
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99815591A
Other languages
English (en)
Chinese (zh)
Inventor
玛丽·柯林斯
德布拉·唐纳德森
洛丽·菲特茨
特玛林·内本
马修·J·惠蒂尔斯
克莱夫·伍德
马歇·威尔斯－卡尔普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Johns Hopkins University
Original Assignee
Genetics Institute LLC
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22786499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1352686(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC, Johns Hopkins University filed Critical Genetics Institute LLC
Publication of CN1352686A publication Critical patent/CN1352686A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN99815591A 1998-12-14 1999-12-13 细胞因子受体链 Pending CN1352686A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21133598A 1998-12-14 1998-12-14
US09/211,335 1998-12-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410767170.2A Division CN104611339A (zh) 1998-12-14 1999-12-13 细胞因子受体链

Publications (1)

Publication Number Publication Date
CN1352686A true CN1352686A (zh) 2002-06-05

Family

ID=22786499

Family Applications (2)

Application Number Title Priority Date Filing Date
CN99815591A Pending CN1352686A (zh) 1998-12-14 1999-12-13 细胞因子受体链
CN201410767170.2A Pending CN104611339A (zh) 1998-12-14 1999-12-13 细胞因子受体链

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410767170.2A Pending CN104611339A (zh) 1998-12-14 1999-12-13 细胞因子受体链

Country Status (16)

Country Link
US (1) US7507706B1 (enExample)
EP (1) EP1141286B1 (enExample)
JP (3) JP5519087B2 (enExample)
CN (2) CN1352686A (enExample)
AT (1) ATE342976T1 (enExample)
AU (1) AU780031B2 (enExample)
BR (1) BR9916209A (enExample)
CA (1) CA2356779C (enExample)
CY (1) CY1107657T1 (enExample)
DE (1) DE69933696T2 (enExample)
DK (1) DK1141286T3 (enExample)
ES (1) ES2277460T3 (enExample)
MX (1) MXPA01006006A (enExample)
NZ (1) NZ512942A (enExample)
PT (1) PT1141286E (enExample)
WO (1) WO2000036103A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827280A (zh) * 2004-06-09 2012-12-19 惠氏公司 针对人白介素-13的抗体及其用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
EP2027867A1 (en) * 2000-10-20 2009-02-25 Genetics Institute, LLC Method and composition for inhibition of tumor growth and enhancing an immune response
EP1587534A1 (en) * 2003-01-17 2005-10-26 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
CA2512808A1 (en) * 2003-01-18 2004-08-12 Marc Elliot Rothenberg Regulation of allergen induced gene
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004092404A2 (en) * 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PL1711528T3 (pl) 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
MX2007005866A (es) 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
EP2162743A4 (en) * 2007-05-29 2010-07-14 Univ Cincinnati METHOD FOR MODULATING IGNITION AND COMPOSITIONS THEREFOR
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
CA3059731A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
CZ283050B6 (cs) 1989-12-20 1997-12-17 Schering Corporation Polypeptid, jeho subsekvence a jejich použití
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5246701A (en) 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
ATE130869T1 (de) 1991-03-29 1995-12-15 Sanofi Sa Protein mit der aktivität vom typ von cytokin, dafür kodierende rekombinante dns, transformierte zellen und mikroorganismen.
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
EP0721346B1 (en) 1993-09-02 1998-06-10 Trustees of Dartmouth College Methods for inducing antigen-specific t cell tolerance
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
EP0907730B1 (en) * 1995-10-23 2009-10-07 Zenyth Operations Pty Ltd Haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1997033913A1 (en) * 1996-03-13 1997-09-18 Zymogenetics, Inc. Cytokine-receptor expressed in testis cells
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
AU6175696A (en) * 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
WO1997047742A1 (en) * 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
TR200001247T2 (tr) 1997-01-10 2002-06-21 Biogen Inc. Anti-CD40L bileşikleri ile lupus nefritis tedavisi.
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
AU5756100A (en) 1999-06-21 2001-01-09 Genetics Institute Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
AU2000278349A1 (en) 1999-09-28 2001-04-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
EP1222212A4 (en) 1999-10-06 2005-05-04 Penn State Res Found MUTANTS OF IL-13
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827280A (zh) * 2004-06-09 2012-12-19 惠氏公司 针对人白介素-13的抗体及其用途

Also Published As

Publication number Publication date
ATE342976T1 (de) 2006-11-15
PT1141286E (pt) 2007-01-31
US7507706B1 (en) 2009-03-24
CN104611339A (zh) 2015-05-13
DK1141286T3 (da) 2007-02-19
EP1141286A1 (en) 2001-10-10
EP1141286B1 (en) 2006-10-18
CA2356779A1 (en) 2000-06-22
AU2177500A (en) 2000-07-03
DE69933696T2 (de) 2007-08-23
CA2356779C (en) 2012-03-13
JP2014113165A (ja) 2014-06-26
AU780031B2 (en) 2005-02-24
DE69933696D1 (de) 2006-11-30
WO2000036103A1 (en) 2000-06-22
WO2000036103A9 (en) 2002-04-11
JP2010263889A (ja) 2010-11-25
CY1107657T1 (el) 2013-04-18
EP1141286A4 (en) 2002-06-26
JP2003511007A (ja) 2003-03-25
JP5519087B2 (ja) 2014-06-11
BR9916209A (pt) 2001-12-26
MXPA01006006A (es) 2004-08-12
NZ512942A (en) 2004-01-30
ES2277460T3 (es) 2007-07-01

Similar Documents

Publication Publication Date Title
CN1352686A (zh) 细胞因子受体链
US20100086516A1 (en) Cytokine receptor chain
CN1268973A (zh) β－淀粉样肽结合蛋白及其编码聚核苷酸
CN1158896A (zh) 新的应激蛋白
AU2005202229B2 (en) Cytokine Receptor Chain
CN1798768A (zh) 抗il－22ra抗体和结合伴侣以及在炎症中的使用方法
CN1164614C (zh) 记忆清除蛋白及其应用
CN1267730A (zh) 一种新的人钾离子通道调节因子蛋白及其编码序列
CN1267732A (zh) 一种人甲基转移酶蛋白及其编码序列
CN1268565A (zh) 一种新的人核糖基化因子蛋白及其编码序列
CN1278002A (zh) 一种人rna结合蛋白及其编码序列
CN1278005A (zh) 一种人核仁染色体蛋白及其编码序列
CN1266898A (zh) 一个新的人羧肽酶前体蛋白及其编码序列
CN1269365A (zh) 一种新的人细胞凋亡相关蛋白及其编码序列
CN1264741A (zh) 一种新的人二磷酸腺苷核糖基葡萄糖水解酶蛋白及其编码序列
CN1271008A (zh) 一种新的人耐盐蛋白亚基蛋白及其编码序列
CN1281044A (zh) 一种人翻译起始因子蛋白及其编码序列
CN1269412A (zh) 一种新的人t细胞受体相关蛋白及其编码序列
CN1278004A (zh) 一种新的人免疫球蛋白受体亚基蛋白及其编码序列
CN1269419A (zh) 一种新的人氮代谢抑制调节因子蛋白及其编码序列
CN1281041A (zh) 一种人补体成分亚基链蛋白异构体及其编码序列
CN1302875A (zh) 人夏科－莱登晶体5及其编码序列,以及制法和用途
CN1269410A (zh) 一种新的人免疫球蛋白受体亚基蛋白及其编码序列
CN1271012A (zh) 一种新的人阳离子转运相关蛋白及其编码序列
CN1268566A (zh) 一种新的人畸胎癌发生相关蛋白及其编码序列

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20020605